Literature DB >> 18372131

The molecular mechanism of gypenosides-induced G1 growth arrest of rat hepatic stellate cells.

Ming-Ho Chen1, Shu-Hsin Chen, Qwa-Fun Wang, Jung-Chou Chen, De-Ching Chang, Shih-Lan Hsu, Ching-Hsein Chen, Chiou-Rong Sheue, Yi-Wen Liu.   

Abstract

AIM OF THE STUDY: Gypenosides, the saponins extract derived from Gynostemma pentaphyllum Makino, have been used for treating hepatitis and cancer in Asia. Our previous study demonstrates that gypenosides inhibit the onset and improve the recovery of liver fibrosis induced by CCl4 in rats. In this study, we used the isolated rat hepatic stellate cells (HSCs) as a model to study the cellular mechanism of gypenosides-inhibited liver fibrosis.
MATERIALS AND METHODS: Rat HSCs was treated with PDGF, gypenosides or vehicle. Cell viability was assessed by trypan blue staining. Apoptosis and cell cycle were evaluated by flow cytometry. The activation or inhibition of signal molecules was detected by Western blotting.
RESULTS: Our results showed that 500 microg/ml gypenosides decreased PDGF-induced rat HSCs numbers (8750+/-2629 versus 103,000+/-6683, p<0.001, 95% confidence interval) and arrested cells at the G1 phase without the presence of sub-G1 fraction. Analysis of PDGF-induced proliferative molecules including phosphorylation of Akt and p70 S6K, gypenosides inhibited the activation of this signal pathway. Furthermore, gypenosides down-regulated the protein expression of cell cycle G1-specific cyclin D1 and D3.
CONCLUSIONS: Gypenosides inhibited PDGF-induced HSCs proliferation by inhibiting the signal pathway of PDGF-Akt-p70 S6K and down-regulation of cyclin D1 and D3 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18372131     DOI: 10.1016/j.jep.2008.02.009

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  8 in total

1.  Gypenosides induce apoptosis by ca2+ overload mediated by endoplasmic-reticulum and store-operated ca2+ channels in human hepatoma cells.

Authors:  Da-Peng Sun; Xiao-Xi Li; Xin-Li Liu; Dan Zhao; Feng-Qi Qiu; Yan Li; Ping Ma
Journal:  Cancer Biother Radiopharm       Date:  2013-05       Impact factor: 3.099

2.  Activation of protein serine/threonine phosphatase PP2Cα efficiently prevents liver fibrosis.

Authors:  Lirui Wang; Xu Wang; Jing Chen; Zhengyi Yang; Liang Yu; Lihong Hu; Xu Shen
Journal:  PLoS One       Date:  2010-12-06       Impact factor: 3.240

Review 3.  Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches.

Authors:  Areeba Ahmad; Riaz Ahmad
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

4.  Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.

Authors:  Gang Yang; Feihua Wu; Minyan Chen; Jian Jin; Rong Wang; Yongfang Yuan
Journal:  Int J Nanomedicine       Date:  2019-04-01

5.  Chinese medicines as a resource for liver fibrosis treatment.

Authors:  Yibin Feng; Kwok-Fan Cheung; Ning Wang; Ping Liu; Tadashi Nagamatsu; Yao Tong
Journal:  Chin Med       Date:  2009-08-20       Impact factor: 5.455

6.  Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.

Authors:  Lulu Kong; Xiaobing Wang; Kun Zhang; Wenjuan Yuan; Qiwen Yang; Jianping Fan; Pan Wang; Quanhong Liu
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

Review 7.  Anti-fibro-hepatocarcinogenic Chinese herbal medicines: A mechanistic overview.

Authors:  Alex Boye; Yan Yang; James Asenso; Wei Wei
Journal:  J Intercult Ethnopharmacol       Date:  2016-06-14

8.  Eleutheroside B Protects against Acute Kidney Injury by Activating IGF Pathway.

Authors:  Hongmei Zang; Qin Yang; Jun Li
Journal:  Molecules       Date:  2019-10-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.